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The functional consequences of the age-associated decline in
IGF-I are unknown. We hypothesized that low IGF-I levels in
older women would be associated with poor muscle strength
and mobility. We assessed this question in a population rep-
resentative of the full spectrum of health in the community,
obtaining serum IGF-I levels from women aged 70–79 yr, en-
rolled in the Women’s Health and Aging Study I or II. Cross-
sectional analyses were performed using 617 women with
IGF-I levels drawn within 90 d of measurement of outcomes.
After adjustment for age, there was an association between
IGF-I and knee extensor strength (P  0.004), but not anthro-
pometry or other strength measures. We found a positive re-
lationship between IGF-I levels and walking speed for IGF-I
levels below 50 g/liter (P < 0.001), but no relationship above
this threshold. A decline in IGF-I level was associated with
self-reported difficulty in mobility tasks. All findings were
attenuated after multivariate adjustment.
In summary, in a study population including frail and healthy
older women, low IGF-I levels were associated with poor knee
extensor muscle strength, slow walking speed, and self-reported
difficulty with mobility tasks. These findings suggest a role for
IGF-I in disability as well as a potential target population
for interventions to raise IGF-I levels. (J Clin Endocrinol Metab
86: 4139–4146, 2001)
ADECLINE IN IGF-I levels has been found to occur withnormal aging, based on cross-sectional studies that
included healthy, community-dwelling older people (1–6).
Such a decline in IGF-I levels may reflect declines in GH
production with age (7). Additionally, IGF-I levels are af-
fected by nutritional status, physical activity level, coexistent
illness, alcohol intake, and liver function (3, 4, 7–12). These
relationships are summarized in Fig. 1.
IGF-I is a potential mediator of alterations in muscle mass
and strength, and thereby of distal outcomes of clinical im-
portance in the elderly, such as objective performance on
muscle-dependent tasks and mobility (Fig. 1). However, the
functional significance of the IGF-I level in older individuals
is unknown. Although biologically plausible, prior observa-
tional studies have been unable to detect a relationship be-
tween IGF-I and body composition or muscle strength after
adjustment for age (2–6, 13). It is possible that these associ-
ations were missed due to selection bias from exclusion of
disabled elderly individuals, narrowing the distribution of
functional status available for analysis. Furthermore, few
studies have attempted to assess the relationships between
IGF-I levels and more distal outcomes, such as performance
tasks and mobility (2, 13, 14). Using a population represen-
tative of the full spectrum of health in older women in the
community, we tested the hypotheses that 1) IGF-I levels
would have a greater range of values and a lower mean value
than those obtained in studies in which subjects in poor
health were not included; and 2) low IGF-I levels would be
associated with low lean body mass, poor muscle strength,




Study subjects were community-dwelling women, 70–79 yr of age,
residing in Baltimore, MD, who were recruited into 2 longitudinal,
population-based companion studies: Women’s Health and Aging
Study I (WHAS I) and Women’s Health and Aging Study II (WHAS II).
The overall objectives of the 2 studies were to determine the etiology of
onset and/or the progression of physical disability. Sampling, recruit-
ment, and study designs for each study have previously been described
in detail (15, 16). For WHAS I, an age-stratified random sample was
selected from the Health Care Financing Administration’s (HCFA)
Medicare enrollment file for the 32,538 women 65 yr or older residing
in 12 contiguous zip codes in Baltimore, MD, yielding 6,521 women to
screen for study eligibility. Exclusion criteria included nursing home
residence or having moved outside the catchment area. A screening
interview in the home, designed to identify the one third most disabled
older women living in the community, was administered to 4,137
women who were eligible for and consented to screening. Physical
disability was identified through self-reported difficulty in 4 domains:
1) mobility tasks, 2) upper extremity tasks, 3) household management
tasks, and 4) basic self-care tasks. Women who reported difficulty in 2,
3, or 4 domains represented the one third most disabled community-
dwelling older women and were eligible for inclusion into WHAS I.
Women with Mini-Mental State Exam scores less than 18 were excluded.
Of the 1,409 who met study eligibility criteria, 1,002 agreed to participate
in the study in 1992. There were no major differences in sociodemo-
graphic or health characteristics between participants and eligible
women who declined. Standardized questionnaires were administered
in the participant’s home by trained interviewers. Two weeks later, a
trained registered nurse conducted an examination of each study par-
ticipant in her home, using a standardized protocol that included
performance-based measures. Approximately 75% of women also con-
sented to phlebotomy in the home at a separate visit, performed by a
trained phlebotomist who followed a standardized protocol.
WHAS II was designed to be a companion study to WHAS I and is
Abbreviations: BMI, Body mass index; HCFA, Health Care Financing
Administration; WHAS, Women’s Health and Aging Study.
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comprised of a cohort of women, aged 70–79 yr, who were selected to
be representative of the two thirds least disabled older women living in
the community. Potential participants were selected via age-stratified
random samples from the same HCFA database as in WHAS I and were
screened by telephone using the same 4 domains of physical function.
Eligible women were asked to participate if they had difficulty in 0 or
1 domain of physical function and scored 24 or higher on a Mini Mental
State Exam. In 1994, 880 women were found eligible for WHAS II, and
436 consented to participate (49.5%). Those agreeing to participate were
more highly educated and had more diseases than those who refused to
participate, but did not differ significantly in disability characteristics.
An interview standardized to that performed in WHAS I was admin-
istered in The Johns Hopkins Functional Status Laboratory. In addition,
trained technicians conducted an examination of each study participant,
using a standardized protocol that included performance-based mea-
sures. Phlebotomy was performed in 93% of WHAS II participants by
a trained phlebotomist following the same protocol as that used in
WHAS I.
For comparability with the WHAS II cohort age range of 70–79 yr, we
only included women from WHAS I if they were also in this age range.
Of the 398 women in WHAS I and 436 women in WHAS II aged 70–79
yr, 325 women in WHAS I and 403 in WHAS II had IGF-I levels mea-
sured. These women are included in the descriptive graph in Fig. 2. For
the regression analyses, participants who had samples obtained within
90 d of the baseline examinations were included (257 women in WHAS
I and 360 women in WHAS II). Women included in either the descriptive
or regression analyses reported slightly less disability in activities of
daily living than those excluded, but did not differ significantly in other
baseline characteristics or measured outcomes from women included in
the original parent WHAS I or II studies.
Variables
The weekly level of leisure time physical activity was determined
using the modified Minnesota Leisure Time Activities Questionnaire
(17). A weighted score of kilocalories expended per wk was calculated
from questions on frequency and duration of walking for exercise,
dancing, bowling, performing moderately strenuous household and
outdoor chores, and participating in any regular exercise program. The
number of comorbid illnesses was based on self-report of prior physician
diagnosis of myocardial infarction, angina, congestive heart failure, high
blood pressure, other heart disease, diabetes, arthritis, stroke, cancer, hip
fracture, Parkinson’s disease, or lung disease. Self-assessed health was
categorized as excellent, very good, good, fair, or poor by the partici-
pants and recoded as excellent-very good, good, and fair-poor. Physical
function was ascertained with standardized questions regarding diffi-
culty with specific aspects of mobility function, which began with “by
yourself, that is without help from another person or special equipment,
do you have any difficulty,” and were completed with 1) “lifting or
carrying something as heavy as 10 pounds, for example, a bag of gro-
ceries?” 2) “walking for a quarter of a mile, that is about 2–3 blocks?”
3) “walking up 10 steps without resting?” 4) “getting in and out of bed
or chairs?” or 5) “doing heavy housework such as washing windows,
walls, or floors?” Responses were categorized dichotomously as yes
or no.
Height and weight were measured with the participant standing in
stocking feet wearing light indoor clothing. The participant’s head was
positioned against a level doorway using a Frankfort plane, and height
was measured to the nearest centimeter using a stadiometer. Weight was
measured in kilograms using a digital scale. Triceps skinfold thickness
was measured at the midpoint of the upper right arm with a Holtain
skinfold calipers (Seritex, Carlstadt, NJ) to the nearest 0.2 mm in accor-
dance with standard procedures (18). If the difference between the first
and the second reading exceeded 2.0 mm, a third reading was per-
formed. Skinfold thickness values represent the mean of all (two or
three) measurements obtained. Arm circumference was measured with
a measuring tape to the nearest 0.1 cm at the midpoint of the upper right
arm. If the difference between the first and the second reading exceeded
0.8 cm, a third reading was performed. Arm circumference values rep-
resent the mean of all (two or three) measurements obtained. A calcu-
lated arm muscle area was obtained using the equation reported by
Heymsfield et al. (19).
Blood samples were collected between 0900–1400 h in a nonfasting
state, processed, frozen, and sent the same day to Quest Diagnostic
Laboratories (Teeterboro, NJ). The serum IGF-I level was measured by
RIA with ethanol extraction (Nichols Institute Diagnostics, San Juan
Capistrano, CA). The overall coefficient of variation was less than 15%,
and the assay sensitivity 0.1 g/liter. Serum albumin was measured
using a colorimetric assay.
Data on maximal grip strength were obtained using a JAMAR hand-
held dynamometer (model BK-7498, Fred Sammons, Inc., Burr Ridge,
IL). Grip strength was measured 3 times with each hand. The best
measure in the stronger hand is reported. Knee extensor (quadriceps)
and hip flexor (iliopsoas) muscle strengths were determined using a
Nicholas Manual Muscle Tester dynamometer (model BK-7454, Fred
Sammons, Inc.). Tests were conducted with the participant seated com-
fortably in a hard chair and hips and knees flexed at 90 °. The dyna-
mometer was placed a few inches above the right ankle between the
medial and lateral malleolus for the knee extension test and immediately
proximal to the femoral condyles at the distal thigh for the hip flexion
test. Participants were instructed to push against the dynamometer as
hard as they could, and the examiner then pushed hard enough to break
the contraction. Each test was performed twice for each leg. The best
measure for the stronger leg is reported. Interrater reliability of strength
tests was assessed in a pilot study of 22 women: the intraclass correlation
coefficient was 0.91 for knee extension and 0.93 for hip flexion (20).
The participant was timed walking over a 4-meter course. For a small
group of women in WHAS I, adequate space was not available in the
home, and a 3-meter course was used. Participants were instructed to
stand with both feet at the starting line and to start walking after a
specific verbal command. The subject could use a cane, a walker, or other
walking aid, but not the aid of another person. The times to complete
the first meter and the entire course were recorded at both a rapid and
a usual pace. The length of the walk in meters divided by the time in
seconds was used to calculate the walking speed. For the chair stand test,
participants were asked to sit with their arms folded across their chests
in a straight-backed chair placed against a wall and to stand and sit as
quickly as possible five times in a row.
FIG. 1. Proposed causal pathway of the GH axis in frailty.
FIG. 2. Cross-sectional distribution of IGF-I levels by age, weighted
to represent the original population sampled.
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Data analysis
We first compared baseline characteristics between WHAS I and
WHAS II; t tests were used for continuous variables, and 2 tests were
used for categorical variables, to test differences between study popu-
lations. IGF-I levels were log-transformed for all analyses to normalize
their skewed distribution. Two extreme outliers values above 400 g/
liter were included in analyses, as we were unable to confirm that these
values were erroneous. The effect of inclusion of these individuals was
minimized by log transformation of IGF-I, and their inclusion had nei-
ther a clinically nor a statistically significant impact on our analytic
results. All categorical variables were coded as indicator variables.
Regression analyses were used to investigate associations between
outcome variables and IGF-I, adjusting for age and other covariates.
Linear regressions were fit to describe anthropometry, strength, and
performance outcomes, and logistic regressions were fit to describe
self-report of difficulty. Scatterplot matrixes and analyses by quintiles
were performed to check for potential nonlinear associations between
IGF-I and all outcomes. Spline terms (21) were fit if a nonlinear asso-
ciation was evident in plotting and quintile analyses and were main-
tained if they improved the F test of the overall model. These allowed
different slopes vs. log IGF-I above vs. below a given threshold value of
log IGF-I; separate models were fit using threshold values of IGF-I from
50–100 g/liter in 10-U increments, and the model with the best fit
(largest model F statistic) was selected. Data are presented with and
without spline terms for all analyses in which splines were used. Partial
residual plots (22) were used to display data from models with and
without spline terms. Regression analysis residuals are the deviations
between response data and their predicted values based on the regres-
sion model. Hence, if predictions accurately describe relationships be-
tween response variables and covariates, residuals should have no sys-
tematic relationship to covariate values. Lines displaying the model term
for log IGF-I and the 95% confidence band, centered at the spline break-
point, were superimposed on the partial residual plot. All P values are
two-tailed and are presented analyzing log-transformed IGF-I as a con-
tinuous predictor variable. To aid in interpretation of the data, anthro-
pometry and muscle strength dynamometer results are displayed using
the predicted response obtained by inserting the mean level for each
covariate into the model. For logistic regression analyses we report odds
ratios for a decline in IGF-I level of 50 g/liter (1 sd) to provide clinically
relevant estimates. No adjustment was made for multiple comparisons;
findings were assessed for coherence and consistency with theory, rather
than by focusing on isolated P values.
To appropriately reference inferences derived from the combined
data back to the sampling population of community-dwelling women,
aged 70–79 yr, study-specific probability weights were used. Construc-
tion of the weights has been detailed previously (16, 23). Probability
weights were incorporated into all of our descriptive and regression
analyses using the survey weighting capability provided by Stata sta-
tistical software (24), which weights each woman’s data to count pro-
portionately in the analysis for the number of women she represents in
the sampling frame and generates ses that correctly represent the re-
sulting coefficient variability. No qualitative differences in results were
obtained in analyses without the probability weights.
Results
Baseline characteristics
Table 1 shows the baseline characteristics of the 617
women, aged 70–79 yr, who participated in WHAS I or
WHAS II and whose phlebotomy was within 90 d of mea-
surement of all outcomes. The WHAS I cohort, which was
designed to include the one third most disabled community
dwelling women, had a lower percentage of Caucasians,
fewer high school graduates, lower income, less daily activ-
ity, and more medical diagnoses than their WHAS II coun-
terparts of the same age (P  0.01). In addition, WHAS I
women had worse self-reported health, greater difficulty
with activities of daily living, and greater difficulty with
mobility-related tasks than did WHAS II women (P  0.01).
These attributes are reflected in their strength and perfor-
mance measurements; WHAS I women were weaker and
slower than the women of WHAS II (P  0.01).
IGF-I measurements and age
The range of IGF-I values in the 728 women who had IGF-I
levels drawn at baseline in WHAS I or II was 12.8–461.3
g/liter. Using probability weighting to adjust for sample
design and differential nonresponse (25), we obtained an
approximation of the population distribution of IGF-I levels
in community-dwelling women between the ages of 70 and
79 yr (Fig. 2). The mean IGF-I value was 123.6  51.8 (sd)
g/liter. Over the 10-yr span represented, IGF-I levels did
not change with age. Fourteen percent of the IGF-I levels
were below the age-specific normal lower limit of the assay
(71 g/liter).
TABLE 1. Baseline characteristics of 70- to 79-yr-old women in
WHAS I (moderately to severely disabled women) and WHAS II
(not or mildly disabled)




Age (yr) 74.2 (2.7)a 74.0 (2.7)b
Race (% Caucasian) 70 83
Education (% high school grad) 36 74
Income (% $10,000/yr) 46 26
Activity
Kcal expended/wk 657 (1184) 1182 (1339)
Health status
No. of medical diagnoses 3.0 (1.6) 1.9 (1.3)
Self-reported health (%)
Excellent or very good 13 51
Good 34 39
Fair or poor 53 10
Difficulty in at least 1 ADL (%) 60 11
Biochemical measurements
Serum albumin (g/liter) 40 (3) 43 (3)
Serum IGF-I (g/liter) 119.2 (61.1) 122.4 (44.4)b
Physical characteristics
Wt (kg) 72.2 (18.2) 68.1 (13.0)
Ht (cm) 157.1 (6.6) 160.4 (6.0)
BMI (kg/m2) 29.2 (7.2) 26.5 (5.0)
Arm muscle area (cm2) 45.8 (18.4) 38.8 (11.1)
Strength by dynamometer (kg)
Grip 22.1 (5.2) 25.7 (4.9)
Knee extension 13.9 (5.4) 21.5 (5.8)
Hip flexion 11.3 (5.3) 18.9 (8.2)
Performance measures
Walking speed (m/sec)
Rapid pace 4-m walk 1.04 (0.43) 1.51 (0.39)
Usual pace 4-m walk 0.66 (0.28) 1.02 (0.27)
5 chair stand speed (stands/sec) 0.36 (0.08) 0.40 (0.09)
Self-reported difficulty in
physical functions (%)
Getting in/out of a chair 33 3
Walking up 10 steps 53 7
Lifting/carrying 10 lb 67 10
Walking 2–3 blocks 75 12
Heavy housework 79 20
ADL, Activities of daily living.
a Expressed as mean, with SD in parentheses.
b P  0.42 for age, P  0.45 for IGF-I, P  0.01 for all other
variables.
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Relationship between IGF-I and anthropometry measures
Tables 2 and 3 show the age-adjusted and multivariate-
adjusted means, respectively, for measures of anthropome-
try by quintile of IGF-I value. There was no statistically
significant relationship between IGF-I levels and body mass
index (BMI), triceps skinfold measurement, or arm muscle
area calculation in age-adjusted or multivariate-adjusted
analyses. These values reflect the expected impact that vari-
ation in IGF-I values has on each measure when holding
constant each of the other covariates at the group mean. For
example, for a woman of average age, the predicted BMI is
27.1 kg/m2 given an IGF-I level in the first quintile; it is 27.6
kg/m2 given an IGF-I level in the second quintile, an incre-
mental difference of only 0.5 kg/m2. The values of the log
IGF-I coefficient and the P value for IGF-I as a continuous
measure are also shown.
Relationship between IGF-I and muscle strength measures
Predicted mean values of each of the muscle strength
measures at each quintile of IGF-I level are shown in Tables
2 and 3 for a woman with average values of each of the
covariates included in the analyses. In age-adjusted analyses,
the IGF-I level was associated with knee extensor strength of
the dominant leg (P  0.004), although not with grip or hip
flexor strength (Table 2). As shown in Table 3, the association
of IGF-I with knee extensor strength was attenuated after
adjustment for markers of activity level, nutritional status,
comorbid illness, and chronic disease (P  0.07). No im-
provement in either age-adjusted or multivariate-adjusted
models was seen with fitting spline terms.
Relationship between IGF-I and performance-
based measures
The level of IGF-I was weakly associated with walking
speed in the age-adjusted analyses, with slopes indicating
slight improvements in walking speed with increases in the
natural log of the IGF-I level (Table 4). This relationship lost
statistical significance after adjustment for other covariates.
Figure 3A displays a representative partial residual plot for
the multivariate-adjusted rapid pace 4-meter walk. These
data and the others for walking speed suggested that there
was a potentially different relationship between IGF-I and
walking speed in those with the lowest IGF-I values com-
pared with the remainder of the women studied. When we
fit a spline term at a natural log of 3.91, which corresponds
to an IGF-I level of 50 g/liter, we found a positive rela-
tionship between IGF-I and all measures of walking speed in
the 35 women with levels below that threshold level, and no
relationship for IGF-I levels above 50 g/liter (Table 4). The
partial residual plot for the rapid 4-meter walk allowing
different relationships with IGF-I above and below 50 g/
liter is shown in Fig. 3B. To illustrate the clinical difference
below and above the threshold point, an increase in IGF-I
level from 20 to 50 g/liter was associated with a 0.60 m/sec
(1.3 sd) increase in walking speed on the 4-meter rapid walk,
whereas no change in walking speed was seen for an anal-
















BMI (kg/m2) 0.61 0.33 27.1 27.6 27.4 27.4 28.0
Triceps skinfold (mm) 0.15 0.06 22.2 23.0 24.3 23.0 24.5
Arm muscle area (cm2) 0.42 0.79 42.3 41.4 41.6 41.7 41.4
Muscle strength (kg)
Grip 0.85 0.09 23.2 24.5 25.5 24.2 24.4
Knee extensor 1.80 0.004 17.2 18.8 19.5 18.9 19.9
Hip flexor 0.63 0.39 15.2 16.5 17.3 15.5 16.4
a From multiple linear regression of response variable on IGF-I, adjusting for age. The IGF-I coefficient estimates the value by which the
average response varies per unit variation in log IGF-I, holding age constant.
b Estimated from regression model, holding age constant at the overall mean age.
















BMI (kg/m2) 0.77 0.19 26.7 27.9 27.8 27.6 27.9
Triceps skinfold (mm) 0.11 0.19 22.4 23.3 24.3 22.9 24.1
Arm muscle area (cm2) 0.50 0.67 41.2 42.0 42.3 41.9 41.4
Muscle strength (kg)
Grip 0.52 0.31 23.4 24.3 25.3 24.1 24.4
Knee extensor 1.10 0.07 17.8 18.7 19.1 18.6 19.7
Hip flexor 0.04 0.96 15.7 16.4 17.0 15.4 16.3
a From multiple linear regression of response variable on IGF-I, adjusting for age, serum albumin level, activity level, number of comorbid
illnesses, and self-assessed health. The IGF-I coefficient estimates the value by which the average response varies per unit variation in log IGF-I,
holding adjustment variables constant.
b Estimated from regression model, holding each variable constant at the overall mean of the variable.
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ogous increase in log units, from 50 to 125 g/liter, using the
multivariate-adjusted model. We found a similar relation-
ship in analyses of IGF-I and chair stand speed in a five-
repetition chair stand; here, the best fitting model was at a
threshold IGF-I value of 70 g/liter (Table 4), with 95 women
with IGF-I values less than 70 g/liter.
Relationship between IGF-I and self-report of difficulty in
physical function
To explore the relationship between IGF-I and outcomes
distal in our pathway, we examined the association between
IGF-I levels and self-reported difficulty in physical function.
Five questions on mobility tasks were used as dichotomous
outcomes (difficulty or no difficulty) in age-adjusted and
multivariate-adjusted logistic regression analyses. Table 5
presents the age- and multivariate-adjusted associations be-
tween IGF-I and difficulty in specific tasks. A 50-U decline in
IGF-I levels from the mean value of 123.6 g/liter was as-
sociated with a 12–59% increase in the odds of reporting
difficulty in each of the tasks in the age-adjusted analyses.
These values achieved statistical significance for getting in or
out of a chair, difficulty walking up 10 steps, and performing
heavy housework (P  0.05). In the multivariate analyses, the
associations were attenuated for all tasks. However, statis-
tical significance persisted for 2 tasks, with a 42% increase in
difficulty getting in or out of a chair (P  0.007) and a 31%
increase in the odds of reporting difficulty walking up 10
steps (P  0.05).
Discussion
In this combined cohort spanning the full range of physical
function in community-dwelling older women, we found a
wider range of IGF-I values and a lower mean value than
those reported in prior cohort studies (3, 4); the exception is
1 study of 77 women over the age of 65 yr with functional
limitations, who had a mean level of 110.9 g/liter (13). In
addition, we are the first, to our knowledge, to find associ-
ations between IGF-I and knee extensor strength and be-
tween IGF-I and self-reported function on several mobility-
related tasks over the entire range of IGF-I values. Finally, we
described an association between IGF-I level and walking
and chair stand speed specific to levels below the reported
age-specific normal range. These findings were attenuated
after adjustment for markers of activity level, nutritional
status, comorbid illness, and chronic disease.
IGF-I levels have been reported to decline with age, based
on cross-sectional data from several cohort studies of older
individuals (1–6). We report a wide range of IGF-I levels in
the older women studied here, with a significant percentage
(14%) below the assay range of 71–290 g/liter specified by
Nichols. This assay range was originally determined based
on 123 healthy men and women between the ages of 55 and
85 yr, using the levels of the middle 95% of values to define
normal. Using the same criteria in the 728 women, aged
70–79 yr, in WHAS I and II, the normal range could be
considered to be 47–203 g/liter, considerably lower than
the current range. However, this method of determining the
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levels defined as abnormal and therefore may not be clini-
cally appropriate or meaningful.
The clinical significance of an abnormal IGF-I level in an
older individual is unknown. Because of the trophic effects
of GH and IGF-I on muscle, it has been suggested that low
IGF-I levels could result in adverse clinical consequences.
Prior observational studies in large cohorts of elderly people
have been unable to support relationships between the IGF-I
level and measures of body composition or muscle strength
after adjustment for age (2–6, 13). A potential explanation for
this is the homogeneity of these outcomes in these relatively
healthy older individuals. We were also unable to find an
association in this present study between IGF-I levels and the
anthropometry measures obtained in WHAS I and II: BMI,
triceps skinfold, and arm muscle area. It is possible that other
measurements that more precisely assess muscle and fat
mass might make these relationships apparent. BMI is a poor
marker for lean body mass, the skinfold measurement was
performed using calipers at a single site, and the arm muscle
area was calculated from triceps skinfold and arm circum-
ference measurements using a formula that is not well val-
idated in older individuals (19).
Our finding of a relationship between IGF-I levels and
knee extensor strength suggests a role for IGF-I in the quad-
riceps muscle. However, we have difficulty explaining the
lack of the consistency using other dynamometer measures
of grip and iliopsoas strength, so that the isolated strength
finding must be interpreted with caution. It is possible that
the effects of arthritis diminished the validity of dynamom-
eter testing of muscle strength, an insurmountable problem
in testing older individuals. However, after exclusion of par-
ticipants who reported pain in the joint with strength testing,
the reported relationships were unchanged (data not shown).
Because of the large number of women available for our
analyses, we were able to examine associations between
IGF-I and mobility outcomes in women with low IGF-I levels.
Clinical trials of GH therapy in older individuals have found
modest improvements in the percentage of muscle mass or
muscle strength using small numbers of healthy volunteers
(26–29). Our analyses support the potential for a threshold
of IGF-I values, below which clinically significant effects
would be obtained from modest improvements in IGF-I
level, but above which such effects would be unapparent.
The specific threshold values identified in this investigation
represent the best estimates from our data and are imprecise
secondary to a limited number of WHAS participants at low
IGF-I levels. The difference in threshold level that we found
between walking speed and chair stand speed may also
reflect this limitation. However, although we cannot pre-
cisely identify the threshold point, in sensitivity analyses in
which we removed the lowest values of IGF-I, the presence
of a threshold effect was upheld.
No prior studies of IGF-I in older women have used a
study population with as wide a spectrum of physical func-
tion as our cohort. WHAS II, which was designed to include
the two thirds least disabled women living in the community,
is comprised of a study population that is typical of healthy
older women who are usually included in epidemiological
studies. WHAS I, as a cohort designed to represent the one
third most disabled women living in the community, is com-
prised of a group of women who are ordinarily difficult to
access for research studies. The use of sampling from the
HCFA database instead of volunteer recruitment mecha-
FIG. 3. Partial residual plots for rapid 4-m walking speed for models assuming linear (A) and spline (B) relationship with log IGF-I, respectively.
The y-axis values are predicted walking speed, adjusting out contributions for all other covariates in the model and centered around predictions
at log IGF-I  3.91. The darker solid line plots model terms involving log IGF-I; the small triangles plot these terms plus model residuals. The
lighter solid lines represent a 95% confidence band for predicted centered walking speed, adjusted for all other covariates in the model. A well
fitting model should have plotted triangles distributed evenly around the solid line. In contrast, the leftmost triangles in A predominantly fall
below the line, suggesting the need for the nonlinear model in B.
TABLE 5. Odds ratios of self-reported difficulty in physical
function associated with a 50 g/liter decline in IGF-I level from
the mean
Task Age-adjusted[OR (95% CI)]
Multivariate-adjusted
[OR (95% CI)]
Getting in/out of a
chair
1.59 (1.26–2.02)a 1.42 (1.10–1.83)a
Walking up 10 steps 1.41 (1.12–1.77)a 1.31 (1.00–1.70)a
Lifting/carrying 10 lb 1.21 (0.98–1.49) 0.99 (0.78–1.20)
Walking 2–3 blocks 1.12 (0.92–1.38) 0.92 (0.73–1.17)
Performing heavy
housework
1.23 (1.01–1.50)a 1.09 (0.86–1.39)
a P  0.05.
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nisms as well as home visits instead of travel to a study clinic
enabled us to enroll women who ordinarily exclude them-
selves from research studies. Our findings were not present
if we performed our analyses in WHAS II alone, but required
the broader range of IGF-I values and function resulting from
inclusion of both WHAS I and II. In addition, using infor-
mation in the HCFA database, we were able to extrapolate
back to the original population eligible for enrollment using
weighting procedures to account for missing women. How-
ever, because our study sample was limited to women be-
tween the ages of 70–79 yr, our findings may not be gener-
alizable to women outside this age range or to men.
There is considerable controversy regarding the use of the
IGF-I level as a measure of GH status. Multiple GH-inde-
pendent factors have been reported to affect IGF-I levels,
including nutritional status, comorbid illness, liver function,
and alcohol intake (3, 4, 7–12). We attempted to account for
these confounding influences in our multivariate analyses by
controlling for albumin level, a calculated activity level based
on self-reported function, the number of physician-diag-
nosed illnesses, and self-reported health. Additional analy-
ses in which we excluded those with abnormal transaminase
levels or alcohol intake above 14 drinks/wk did not alter our
findings (data not shown). The magnitude of the IGF-I effect
was attenuated in all analyses after multivariate adjustment,
and in several analyses, associations seen after adjustment
for age alone lost statistical significance. These findings sug-
gest that the IGF-I level is an aggregate marker for poor
nutrition, low activity, and comorbid illness. For other rela-
tionships, in which the statistically significant association
persisted after multivariate adjustment, two possibilities ex-
ist: there is an independent association of IGF-I with strength,
muscle performance, and mobility; or residual confounding
remains due to the crudity of measurement of our covariates
or from other, unknown covariates not included in our
model.
To our knowledge, we are the first to report an association
between a decline in IGF-I levels and difficulty in strength
and mobility-related functional outcomes. Although biolog-
ically plausible, a causal relationship between IGF-I and our
outcomes cannot be proven from this study due to its cross-
sectional design. Should these preliminary findings be con-
firmed in longitudinal analyses, other observational studies,
and clinical trials, this would suggest a potential impact of
raising IGF-I levels on the quality of life of older individuals.
There has been appropriate caution regarding the adminis-
tration of GH to older people, including concern over del-
eterious side-effects, promotion of growth of underlying ma-
lignancies, inconvenience of administration, and prohibitive
cost. Moreover, the value of r2 was less than 3% for all
unadjusted models, which demonstrates that the IGF-I level
predicts little of the variance in muscle measures. This find-
ing reflects the multiple factors that are important in deter-
mination of muscle strength and function and suggests that
current knowledge is insufficient to identify a target group
in whom administration of GH could be expected to con-
sistently improve strength outcomes. Although this finding
cautions against the present utility of IGF-I for diagnosing or
predicting functional outcomes clinically, it does not dimin-
ish the validity of our findings of population level trends in
strength and function with IGF-I levels. At the population
level, the confidence intervals about estimated spline func-
tions strongly supported a substantial decline in average
walking speed and chair stands in association with suffi-
ciently low thresholds of IGF-I. Hence, the potential exists for
identifying target groups who could benefit from interven-
tions that raise IGF-I levels. Newer GH secretagogues show
promise as more acceptable therapies for intervention (30).
Continued investigation for an appropriate target group of
older individuals for interventions to improve mobility is
warranted in parallel with development of new hormonal
pharmacological therapies.
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